Companies / BOC Sciences / Anrukinzumab
BOC Sciences

Anrukinzumab | BOC Sciences

Anrukinzumab is a humanized monoclonal antibody that targets and inhibits IL-13. Anrukinzumab has been investigated for the treatment of ulcerative colitis and asthma.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.